An Investigation on the Therapeutic Effect of Thymosin β4 and Its Expression Levels in Streptozotocin-Induced Diabetic Mice

Thymosin β4 (Tβ4) treatment was known to show the potential therapeutic effects on diabetic complications. This study was performed to determine if Tβ4 expression is changed in both serum and tissues under diabetic conditions and can be a serum biomarker. Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight. The mice were sacrificed at 16 weeks after STZ injection. Tissues and plasmas were obtained to determine the expression levels of Tβ4 using ELISA, real time RT-PCR, and immunohistochemistry. The average serum glucose level was increased to approximately 400 mg/dL beginning 2 weeks after the five injections of STZ and lasting for at least 13 weeks until sacrifice. The plasma and tissue levels of Tβ4 in the age-matched control mice were not significantly different from those of the diabetic mice. In conclusion, the Tβ4 expression level in the plasmas and tissues of diabetic mice was not affected by diabetic conditions. It indirectly suggests that the therapeutic effect of Tβ4 on diabetic complications is due to its regenerative effects on damaged tissue but not to the changed expression level of Tβ4 in plasma and tissues of diabetes.

[1]  C. L. Drum,et al.  Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations , 2018, Expert opinion on biological therapy.

[2]  Y. H. Lee,et al.  PGC1α Activators Mitigate Diabetic Tubulopathy by Improving Mitochondrial Dynamics and Quality Control , 2017, Journal of diabetes research.

[3]  M. Chopp,et al.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline. , 2017, Journal of neurosurgery.

[4]  E. Cardona-Muñoz,et al.  Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function , 2016, Journal of diabetes research.

[5]  N. Sebire,et al.  Loss of endogenous thymosin β4 accelerates glomerular disease , 2016, Kidney international.

[6]  Chang Nam Kim,et al.  Increased Expression of Thymosin β4 Is Independently Correlated with Hypoxia Inducible Factor-1α (HIF-1α) and Worse Clinical Outcome in Human Colorectal Cancer , 2016, Journal of pathology and translational medicine.

[7]  P. Riley,et al.  Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart , 2015, Expert opinion on biological therapy.

[8]  M. Chopp,et al.  Therapeutic Benefit of Extended Thymosin β4 Treatment Is Independent of Blood Glucose Level in Mice with Diabetic Peripheral Neuropathy , 2015, Journal of diabetes research.

[9]  Jian Zhu,et al.  Thymosin &bgr;4 Attenuates Early Diabetic Nephropathy in a Mouse Model of Type 2 Diabetes Mellitus , 2015, American journal of therapeutics.

[10]  J. Kwon,et al.  Effect of thymosin beta 4 in the presence of up-regulation of the insulin-like growth factor-1 signaling pathway on high-glucose-exposed vascular endothelial cells , 2015, Molecular and Cellular Endocrinology.

[11]  Young-Kyu Park,et al.  Thymosin β4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/β-catenin signaling pathway. , 2014, Biochemical and biophysical research communications.

[12]  M. Chopp,et al.  Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice , 2012, Neurobiology of Disease.

[13]  Harmanpreet Kaur,et al.  Platelet function and thymosin β4 , 2012, Biological chemistry.

[14]  Yong-Beom Park,et al.  Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy , 2012, Clinical Rheumatology.

[15]  Jian Zhu,et al.  Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. , 2012, Diabetes research and clinical practice.

[16]  Yeon-Ah Lee,et al.  Increased levels of thymosin β4 in synovial fluid of patients with rheumatoid arthritis: association of thymosin β4 with other factors that are involved in inflammation and bone erosion in joints , 2011, International journal of rheumatic diseases.

[17]  J. Jonas,et al.  Intraocular expression of thymosin β4 in proliferative diabetic retinopathy , 2011, Acta ophthalmologica.

[18]  S. Lunin,et al.  Thymus hormones as prospective anti-inflammatory agents , 2010, Expert opinion on therapeutic targets.

[19]  P. Qiu,et al.  Biological activities of thymosin ß4 defined by active sites in short peptide sequences , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  B. Manconi,et al.  Different Thymosin Beta 4 Immunoreactivity in Foetal and Adult Gastrointestinal Tract , 2010, PloS one.

[21]  Y. Liu,et al.  Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure. , 2010, World journal of gastroenterology.

[22]  D. Aronson.  Hyperglycemia and the pathobiology of diabetic complications. , 2008, Advances in cardiology.

[23]  H. Cha,et al.  Thymosin Beta 4 Induces Hair Growth via Stem Cell Migration and Differentiation , 2007, Annals of the New York Academy of Sciences.

[24]  Yeon-Ah Lee,et al.  Anti-inflammatory effects of an ethanolic extract from Clematis mandshurica Rupr. , 2006, Journal of ethnopharmacology.

[25]  H. Kleinman,et al.  Role of Thymosin β4 in Tumor Metastasis and Angiogenesis , 2003 .

[26]  H. Kleinman,et al.  Thymosin β4 Accelerates Wound Healing , 1999 .

[27]  H. Jörnvall,et al.  Biochemical and antibacterial analysis of human wound and blister fluid. , 1996, European journal of biochemistry.

[28]  Y. Wang,et al.  Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Hollander,et al.  Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease. , 1988, Clinical immunology and immunopathology.

[30]  G. Goodall,et al.  Production and characterization of antibodies to thymosin beta 4. , 1983, Journal of immunology.

[31]  B. Horecker,et al.  Thymosin beta 4: a ubiquitous peptide in rat and mouse tissues. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Kleinman,et al.  Thymosin β4 Promotes Dermal Healing. , 2016, Vitamins and hormones.

[33]  Yingwei Chen,et al.  Thymosin β4: a potential molecular target for tumor therapy. , 2012, Critical reviews in eukaryotic gene expression.

[34]  Hiroshi Yamamoto,et al.  Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. , 2011, Journal of biochemistry.

[35]  T. Hara.  Thymosins and muscle regeneration. , 2011, Vitamins and hormones.

[36]  H. Kleinman,et al.  Role of thymosin beta4 in tumor metastasis and angiogenesis. , 2003, Journal of the National Cancer Institute.

[37]  G. Chen,et al.  Effects of thymosin and insulin on suppressor T cell in type 1 diabetes. , 1992, Diabetes research.

[38]  H. Morii,et al.  Protection by thymosin fraction 5 from streptozotocin-induced diabetes in mice. , 1989, Cellular and molecular biology.

[39]  J. Mcmichael.  Coronary artery disease opening remarks. , 1970, Advances in cardiology.